South Carolina is currently home to 1231 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Charleston, Greenville, Spartanburg and Columbia. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI
NCT05220501
Recruiting
OPTIMUM is a study designed to compare the ability of ultra-high resolution transrectal micro-ultrasound (microUS) and multiparametric MRI (mpMRI)/US fusion to guide prostate biopsy.
Gender:
Male
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: Carolina Urologic Research Center, Myrtle Beach, South Carolina
Conditions: Prostate Cancer
Register for Updates
Reducing Metabolic Dysregulation in Dyads
NCT06117241
Recruiting
This study is a 6-month randomized controlled trail of diet modification designed to reduce chronic inflammation and reverse metabolic dysfunction among obese individuals with one or more polyps found at a colonoscopy screening. We also will recruit an at least overweight partner, who lives in the same household. To be eligible, participants will be apparently disease-free, obese AAs or EAs who have self-identified a partner who is at least 9 years, with whom they live and who also is at least o... Read More
Gender:
All
Ages:
Between 9 years and 55 years
Trial Updated:
10/30/2023
Locations: University of South Carolina, Columbia, South Carolina
Conditions: Colorectal Cancer, Inflammation, Nutrition Related Cancer
Register for Updates
Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
NCT02810704
Recruiting
PEPPER is a randomized study comparing the three most commonly used anticoagulants in North America in patients who have elected to undergo primary or revision hip or knee joint replacement surgery. The anticoagulants being compared are enteric coated aspirin, low intensity warfarin, and rivaroxaban.
Gender:
All
Ages:
21 years and above
Trial Updated:
10/30/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Pulmonary Embolism, Venous Thrombosis
Register for Updates
Health Education Approach to Lung Screening
NCT06070870
Recruiting
Evaluate the impact of the patient navigation program on the proportion of patients who complete lung cancer screening (LCS), defined as undergoing a low dose computed tomography (LDCT)
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
10/27/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Lung Cancer
Register for Updates
Hypermobile Ehlers-Danlos Syndrome - Transcutaneous Auricular Neuromodulation
NCT06105541
Recruiting
Investigate whether at-home transcutaneous auricular VNS (tAN: transcutaneous auricular neurostimulation) improves a battery of nine key physical and psychological symptoms of a group of hEDS (Hypermobile Ehlers-Danlos Syndrome & Hypermobile Spectrum Disorder) patients (n=30) using a randomized, double blind, sham controlled design. The study team will collect clinical measures at baseline, after a two-week double-blind intervention phase, after a following two-week open-label phase and finally... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
10/26/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Hypermobile Ehlers-Danlos Syndrome, Hypermobile Spectrum Disorder, Ehlers-Danlos Syndrome
Register for Updates
Impact of Capturing Ictal Events With Ultra-long-term Ambulatory EEG Monitoring With Remote EEG Monitoring System.
NCT06027749
Recruiting
The goal of this clinical trial is to test Epitel's™ Remote EEG Monitoring System's (REMI™) ability to record electroencephalography (EEG) of seizure events in an ambulatory setting for extended periods (14 - 28 days) in patients presenting with questionable seizure characterization. The main questions it aims to answer are: • Can more seizure events be recorded in fourteen (14) days than can be recorded in three (3) days? • Do treating clinicians find clinical value in extended fourteen (14) -... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
10/24/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Epilepsy, Seizures
Register for Updates
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768
Recruiting
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be bette... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: Prisma Health Cancer Institute - Spartanburg, Boiling Springs, South Carolina
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Register for Updates
Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
NCT05617040
Recruiting
This is a multi-centre, Phase 1/2, open-label clinical trial of the VTP-850 prime-boost immunotherapeutic in men with biochemical recurrence after definitive local therapy for prostate cancer.
Gender:
Male
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: Carolina Urologic Research Center, Myrtle Beach, South Carolina
Conditions: Prostate Cancer
Register for Updates
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646
Recruiting
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an... Read More
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
10/24/2023
Locations: ACTION3 Investigational Site 9, Spartanburg, South Carolina
Conditions: FSGS
Register for Updates
Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
NCT05172024
Recruiting
This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals who will enter the cohort with and without SARS-CoV-2 infection and at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection and with or without Post-Acute Sequelae of COVID-19 (PASC) symptoms will be followed to identify risk factors and occurrence of PASC. This study will be conducted in the United States and subjects will be recruited through inpatien... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: Prisma Health Upstate, Greenville, South Carolina
Conditions: SARS-CoV2 Infection
Register for Updates
Stereotactic Ablative Radiation Therapy for Prostate Cancer
NCT05668351
Recruiting
This single arm trial will investigate a novel way to plan and deliver SABR for prostate cancer. Prostate-directed SABR will be high-dose SABR (40 Gy in 5 fractions) with central sparing of the urethra and peripheral sparing of the rectum and pudendal arteries (SUPR-SABR). This study tests the hypothesis that genitourinary (GU) and gastrointestinal (GI) toxicity rates following SUPR-SABR are comparable to (or possibly lower than) historical GU and GI toxicity rates following standard SABR (stSAB... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
10/23/2023
Locations: Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina
Conditions: Prostate Cancer
Register for Updates
A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
NCT04554914
Recruiting
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.
Gender:
All
Ages:
All
Trial Updated:
10/23/2023
Locations: Medical University of South Carolina (Adults and Pediatrics), Charleston, South Carolina
Conditions: Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
Register for Updates